Exchange: NASDAQ·Updated 07:51 PM EST

XNCR News

News
all
press releases
Xencor (NASDAQ:XNCR) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says
JPMorgan Chase & Co. boosted their price target on shares of Xencor from $21.00 to $37.00 and gave the company a "neutral" rating in a research report on Thursday...
MarketBeat
Xencor (NASDAQ:XNCR) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says
JPMorgan Chase & Co. boosted their price target on shares of Xencor from $21.00 to $37.00 and gave the company a "neutral" rating in a research report on Thursday...
MarketBeat
More News
Shares of Xencor, Inc. (NASDAQ:XNCR - Get Free Report) have received a consensus rating of "Moderate Buy" from the eleven ratings firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold...
MarketBeat
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced initial dose-escalation data from its ongoing Phase 1b study of subcutaneous plamotamab, a bispecific CD20 x CD3 T-cell...
Business Wire
Xencor (XNCR) delivered earnings and revenue surprises of +242.86% and +76.89%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the third quarter ended September 30, 2026. Xencors lead CD3 T-cell engaging bispecific antibody...
Business Wire
Xencor reports upbeat Phase 1 kidney cancer data for XmAb819 at ESMO 2026 and selects 400 mcg/kg as the primary proposed Phase 3 study dose.read more...
Benzinga
These biotechnology companies are advancing important developments. NeOnc Technologies Holdings (NASDAQ:NTHI) is outlining plans for a major international brain cancer trial, Azitra (NYSEAMERICAN:AZTR) is preparing human testing of its experimental anti-wrinkle technology, ArriVent BioPharma (NASDAQ:AVBP) is reporting encouraging early response data for its gastrointestinal cancer candidate, Xencor (NASDAQ:XNCR) is advancing its experimental kidney cancer therapy toward a potential registration-enabling study, and SciSparc (NASDAQ:SPRC) is moving closer to patient enrollment in its Phase IIb Tourette syndrome trial.
24-7 Market News
Gainers SciSparc (NASDAQ:SPRC) shares moved upwards by 39.4% to $1.52 during Monday's pre-market session. Xencor (NASDAQ:XNCR) stock moved upwards by 29.46% to $32.6. The company's market cap stands at $1.9read more...
Benzinga
Surgery Partners surged 20.6% on reported $6B Bon Secours deal talks; Scisparc and Xencor led gainers, while XP and others plunged.read more...
Benzinga
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced updated results from the Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with...
Business Wire

Advertisement|Remove ads.